Explore the Agenda

8:30 am Check In, Morning Coffee & Light Refreshments

Workshop A

Workshop A: Discovery

Conjugate Discovery

9:30 am Optimising Payload, Linker & Conjugation Strategies for Next-Generation Bioconjugates

Independent Consultant, Independent Consultant
Oncology Research Intelligence & Modality Intelligence Lead, Astellas Pharma

ADCs have become increasingly sophisticated. Payload selection, linker design, and conjugation chemistries are critical to enhancing efficacy, addressing clinical resistance, and improving the therapeutic index. Join this workshop to explore emerging payload classes, advances in linker design, next-generation conjugation technologies, and dual-payload strategies across ADCs and beyond.

This workshop will explore advances in conjugation chemistry and their implications for ADC design, drug-to-antibody ratio (DAR), and therapeutic properties. 

Key Topics include: 

  • Unlocking novel conjugation, linker design and payloads with established and novel mechanisms of action
  • Unravelling dual-payload ADCs, and bioconjugates designs beyond ADCs
Workshop B
Workshop C
Workshop D

12:00 pm Lunch Break & Networking

Workshop E

Workshop E: Discovery

Design & Combinations

1:00 pm Designing the Next Generation of ADCs: Exploring Novel Constructs & Future Combination Strategies

Senior Scientist, Roche
Principal Scientist, Roche

As the field matures, developers are grappling with two persistent barriers: poor tumor penetration and a treatment landscape that is rapidly filling with combination options. This session brings together perspectives on where next-generation ADC design is heading, from tumor-activated and conditionally active constructs to novel target combinations such as PD-L1/VEGF ADCs positioned as alternatives to bispecifics, and asks what the competitive and combination landscape will look like as these approaches mature.

Learning Takeaways:

  • Understanding the emerging competitive landscape for ADC linker technology, including new protease-specific linkers, and what this means for differentiation against established assets.
  • Exploring practical strategies being developed to address poor tumor penetration, a barrier that continues to limit the efficacy of large molecule ADCs in solid tumors.
  • Considering how novel dual-function constructs, such as a PD-L1/VEGF ADC, could offer a differentiated path compared to bispecific approaches, and what this signals for future combination strategy
Workshop F
Workshop G
Workshop H

3:30 pm End of Post-Conference Workshop Day